Table 2.

The clinical manifestations of myeloperoxidase-ANCA–associated GN in different histopathologic classes

ParametersFocal, n=27Mixed, n=82Crescentic, n=47Sclerotic, n=59P Value
Age, yr50.6±18.947.6±15.450.6±13.143.5±17.70.10
Men, n (%)12 (44.4)31 (37.8)18 (38.3)23 (39.0)0.94
Duration of renal disease, mo1 (1–3)2 (1–3)1 (1–2)1 (1–5)0.10
Hypertension, n (%)11 (40.7)52 (63.4)29 (61.7)48 (81.4)a0.003
BVAS score14 (12–17)14 (12–15)13 (12–16)13 (12–15)0.19
Hemoglobin, g/dl9.6 (7.5–10.7)8.6 (7.4–10.1)8.8 (8.1–10.2)8.3 (6.7–9.9)b0.03
Initial RRT, n (%)2 (7.4)20 (24.4)19 (40.4)a32 (54.2)a,c<0.001
SCr, mg/dl2.3±1.83.7±2.1a4.9±3.0a5.8±3.0a,c<0.001
eGFR<60 ml/min per 1.73 m2, n (%)19 (79.2)72 (87.8)46 (97.9)a58 (98.3)a<0.001
Gross hematuria, n (%)1 (3.7)19 (23.2)26 (55.3)a,c7 (11.9)d<0.001
Urine red blood cell count, ×104/ml200 (85–490)400 (146–960)800 (255–2200)b250 (104–625)e0.002
Urinary protein, g/24 h0.9 (0.6–1.4)2.0 (1.3–3.0)a1.7 (1.2–3.9)a1.9 (1.1–2.9)a<0.001
Serum albumin, g/dl3.6±0.53.4±0.53.5±0.53.4±0.60.32
Extrarenal involvement, n (%)
 Lung12 (44.4)45 (54.9)25 (53.2)30 (50.8)0.81
 Nose11 (40.7)34 (41.5)18 (38.3)18 (30.5)0.59
 Joints2 (7.4)11 (13.4)6 (12.8)5 (8.5)0.75
 Skin4 (14.8)8 (9.8)2 (4.3)9 (15.3)0.25
 Gastrointestinal tract2 (7.4)4 (4.9)0 (0)5 (8.5)0.18
 Fever3 (11.1)12 (14.6)6 (12.8)11 (18.6)0.81
 Others5 (18.5)11 (13.4)7 (14.9)13 (22.0)0.56
  • BVAS, Birmingham vasculitis activity score; SCr, serum creatinine.

  • a Focal versus mixed, crescentic, and sclerotic (P<0.01).

  • b Focal versus mixed, crescentic, and sclerotic (P<0.05).

  • c Mixed versus crescentic and sclerotic (P<0.01).

  • d Crescentic versus sclerotic (P<0.01).

  • e Crescentic versus sclerotic (P<0.05).